Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Lipella's new drug shows promise in treating oral lichen planus, leading to a significant stock surge.

flag Lipella Pharmaceuticals has reported successful Phase 2a trial results for LP-310, a drug treating oral lichen planus, showing significant improvements in pain, inflammation, and ulceration with no serious side effects. flag The company's stock surged over 65% in pre-market trading following the announcement. flag Further trials with higher doses are ongoing.

6 Articles